Exploiting transport activity of P-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists

Molecular Pharmaceutics

Volumn 9, Issue 5, 2012, Pages 1351-1360

  Wittgen, Hanneke G M ^a   Greupink, Rick ^a   Van Den Heuvel, Jeroen J M W ^a   Van Den Broek, Petra H H ^a   Dinter Heidorn, Heike ^b   Koenderink, Jan B ^a   Russel, Frans G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

active transport; baculovirus; blood brain barrier; brain plasma ratio; breast cancer resistance protein; cellular accumulation assay; P glycoprotein; peripheral CB1 receptor antagonist

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CANNABINOID 1 RECEPTOR ANTAGONIST; ELACRIDAR; GLYCOPROTEIN P; PYRAZOLINE DERIVATIVE; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; BACULOVIRUS; BLOOD BRAIN BARRIER; CELL STRAIN HEK293; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG STRUCTURE; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MEMBRANE VESICLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT;

ACRIDINES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; CANNABINOID RECEPTOR ANTAGONISTS; CELL LINE; HUMANS; KINETICS; MALE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PIPERIDINES; PYRAZOLES; QUINIDINE; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY; TETRAHYDROISOQUINOLINES;

EID: 84860783554     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200617z     Document Type: Article

References (35)

1. Di Marzo, V. CB1 receptor antagonism: biological basis for metabolic effects Drug Discovery Today 2008, 13, 1026-1041
2. Boyd, S. T.; Fremming, B. A. Rimonabant-a selective CB1 antagonist Ann. Pharmacother. 2005, 39, 684-690
3. Bifulco, M.; Santoro, A.; Laezza, C.; Malfitano, A. M. Cannabinoid receptor CB1 antagonists: state of the art and challenges Vitam. Horm. 2009, 81, 159-189
4. Jones, D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat. Rev. Drug Discovery 2008, 7, 961-962
5. Nissen, S. E.; Nicholls, S. J.; Wolski, K.; Rodés-Cabau, J.; Cannon, C. P.; Deanfield, J. E.; Després, J. P.; Kastelein, J. J.; Steinhubl, S. R.; Kapadia, S.; Yasin, M.; Ruzyllo, W.; Gaudin, C.; Job, B.; Hu, B.; Bhatt, D. L.; Lincoff, A. M.; Tuzcu, E. M. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial JAMA, J. Am. Med. Assoc. 2008, 299, 1547-1560
6. Silvestri, C.; Ligresti, A.; Di Marzo, V. Peripheral effects of the endocannabinoid system in energy homeostasis: Adipose tissue, liver and skeletal muscle Rev. Endocr. Metab Disord. 2011, 12, 153-162
7. Ward, S. J.; Raffa, R. B. Rimonabant Redux and Strategies to Improve the Future Outlook of CB1 Receptor Neutral-Antagonist/Inverse-Agonist Therapies Obesity (Silver Spring) 2011, 19, 1325-1334
8. Tam, J.; Vemuri, V. K.; Liu, J.; Bátkai, S.; Mukhopadhyay, B.; Godlewski, G.; Osei-Hyiaman, D.; Ohnuma, S.; Ambudkar, S. V.; Pickel, J.; Makriyannis, A.; Kunos, G. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity J. Clin. Invest 2010, 120, 2953-2966
9. Vijayakumar, R. S.; Lin, Y.; Shia, K. S.; Yeh, Y. N.; Hsieh, W. P.; Hsiao, W. C.; Chang, C. P.; Chao, Y. S.; Hung, M. S. Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis and reduces cardiometabolic risk factors Int. J. Obes. 2011, 10.1038/ijo.2011.171
10. Schinkel, A. H. P-Glycoprotein, a gatekeeper in the blood-brain barrier Adv. Drug Delivery Rev. 1999, 36, 179-194
11. Begley, D. J. ABC transporters and the blood-brain barrier Curr. Pharm. Des 2004, 10, 1295-1312
12. Schinkel, A. H.; Wagenaar, E.; Mol, C. A.; van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J. Clin. Invest. 1996, 97, 2517-2524
13. Loscher, W.; Potschka, H. Drug resistance in brain diseases and the role of drug efflux transporters Nat. Rev. Neurosci. 2005, 6, 591-602
14. Tsujikawa, K.; Dan, Y.; Nogawa, K.; Sato, H.; Yamada, Y.; Murakami, H.; Ohtani, H.; Sawada, Y.; Iga, T. Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A Biopharm. Drug Dispos. 2003, 24, 105-114
15. Sadeque, A. J.; Wandel, C.; He, H.; Shah, S.; Wood, A. J. Increased drug delivery to the brain by P-glycoprotein inhibition Clin. Pharmacol. Ther. 2000, 68, 231-237
16. Lange, J. H.; van Stuivenberg, H. H.; Veerman, W.; Wals, H. C.; Stork, B.; Coolen, H. K.; McCreary, A. C.; Adolfs, T. J.; Kruse, C. G. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity Bioorg. Med. Chem. Lett. 2005, 15, 4794-4798
17. El-Sheikh, A. A.; van den Heuvel, J. J.; Koenderink, J. B.; Russel, F. G. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport J. Pharmacol. Exp. Ther. 2007, 320, 229-235
18. Pavek, P.; Merino, G.; Wagenaar, E.; Bolscher, E.; Novotna, M.; Jonker, J. W.; Schinkel, A. H. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo(4,5-b)pyridine, and transport of cimetidine J. Pharmacol. Exp. Ther. 2005, 312, 144-152
19. Wittgen, H. G.; van den Heuvel, J. J.; van den Broek, P. H.; Dinter-Heidorn, H.; Koenderink, J. B.; Russel, F. G. Cannabinoid CB1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4 Drug Metab. Dispos. 2011, 39, 1294-1302
20. van Aubel, R. A.; Koenderink, J. B.; Peters, J. G.; Van Os, C. H.; Russel, F. G. Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells Mol. Pharmacol. 1999, 56, 714-719
21. Cooray, H. C.; Blackmore, C. G.; Maskell, L.; Barrand, M. A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain NeuroReport 2002, 13, 2059-2063
22. Sugimoto, H.; Hirabayashi, H.; Kimura, Y.; Furuta, A.; Amano, N.; Moriwaki, T. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats Drug Metab. Dispos. 2011, 39, 8-14
23. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative Cancer Res. 1993, 53, 4595-4602
24. Lange, J. H.; van der Neut, M. A.; Borst, A. J.; Yildirim, M.; van Stuivenberg, H. H.; van Vliet, B. J.; Kruse, C. G. Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4- carboxamides by fine-tuning their 5-substitution pattern Bioorg. Med. Chem. Lett. 2010, 20, 2770-2775
25. Barna, I.; Till, I.; Haller, J. Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: compound-specific and area-specific distribution within the brain Eur. Neuropsychopharmacol. 2009, 19, 533-541
26. Allen, J. D.; van, L. A.; Lakhai, J. M.; van, d., V; van, T. O.; Reid, G.; Schellens, J. H.; Koomen, G. J.; Schinkel, A. H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C Mol. Cancer Ther. 2002, 1, 417-425
27. Matsson, P.; Pedersen, J. M.; Norinder, U.; Bergstrom, C. A.; Artursson, P. Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs Pharm. Res. 2009, 26 (8) 1816-1831
28. Warren, M. S.; Zerangue, N.; Woodford, K.; Roberts, L. M.; Tate, E. H.; Feng, B.; Li, C.; Feuerstein, T. J.; Gibbs, J.; Smith, B.; de Morais, S. M.; Dower, W. J.; Koller, K. J. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human Pharmacol. Res. 2009, 59, 404-413
29. Uchida, Y.; Ohtsuki, S.; Katsukura, Y.; Ikeda, C.; Suzuki, T.; Kamiie, J.; Terasaki, T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors J. Neurochem. 2011, 117, 333-345
30. Kelder, J.; Grootenhuis, P. D.; Bayada, D. M.; Delbressine, L. P.; Ploemen, J. P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 1999, 16, 1514-1519
31. van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J. R.; Raevsky, O. A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors J. Drug Targeting 1998, 6, 151-165
32. Oostendorp, R. L.; Beijnen, J. H.; Schellens, J. H. The biological and clinical role of drug transporters at the intestinal barrier Cancer Treat. Rev. 2009, 35, 137-147
33. Lin, J. H.; Yamazaki, M. Clinical relevance of P-glycoprotein in drug therapy Drug Metab Rev. 2003, 35, 417-454
34. Pang, Z.; Wu, N. N.; Zhao, W.; Chain, D. C.; Schaffer, E.; Zhang, X.; Yamdagni, P.; Palejwala, V. A.; Fan, C.; Favara, S. G.; Dressler, H. M.; Economides, K. D.; Weinstock, D.; Cavallo, J. S.; Naimi, S.; Galzin, A. M.; Guillot, E.; Pruniaux, M. P.; Tocci, M. J.; Polites, H. G. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice Obesity (Silver Spring) 2011, 19, 1923-1934
35. Quarta, C.; Bellocchio, L.; Mancini, G.; Mazza, R.; Cervino, C.; Braulke, L. J.; Fekete, C.; Latorre, R.; Nanni, C.; Bucci, M.; Clemens, L. E.; Heldmaier, G.; Watanabe, M.; Leste-Lassere, T.; Maitre, M.; Tedesco, L.; Fanelli, F.; Reuss, S.; Klaus, S.; Srivastava, R. K.; Monory, K.; Valerio, A.; Grandis, A.; De, G. R.; Pasquali, R.; Nisoli, E.; Cota, D.; Lutz, B.; Marsicano, G.; Pagotto, U. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance Cell Metab. 2010, 11, 273-285